Expertise in
16
conditions

Paolo De Fabritiis

Rome, IT 
Expertise in
16
conditions
Rome, IT 
OverviewLocationsClinical Research

Overview

Paolo De Fabritiis practices in Rome, Italy. Mr. De Fabritiis is highly rated in 16 conditions, according to our data. His top areas of expertise are Leukemia, Chronic Myelomonocytic Leukemia (CMML), Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Vertebroplasty.

His clinical research consists of co-authoring 157 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Rome, 00133, Italy
Other Locations
Ravenna, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)
Enrollment Status: Terminated
Publish Date: April 10, 2025
Intervention Type: Drug
Study Drugs: SY-1425+Azacitidine, Azacitidine
Study Phase: Phase 3
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: August 27, 2024
Intervention Type: Drug
Study Drugs: Cedazuridine, Decitabine
Study Phase: Phase 3
Phase I Protocol of Adoptive Immunotherapy With Enriched and Expanded Autologous Natural Killer (NK) Cells for Patients With Ph+ Acute Lymphoblastic Leukemia (ALL) in Complete Hematologic Remission (CHR) But With Persistent/Recurrent Minimal Residual Disease (MRD) ≥60 Years or Not Eligible for Other Post-CHR Treatment Modalities
Phase I Protocol of Adoptive Immunotherapy With Enriched and Expanded Autologous Natural Killer (NK) Cells for Patients With Ph+ Acute Lymphoblastic Leukemia (ALL) in Complete Hematologic Remission (CHR) But With Persistent/Recurrent Minimal Residual Disease (MRD) ≥60 Years or Not Eligible for Other Post-CHR Treatment Modalities
Enrollment Status: Completed
Publish Date: March 30, 2023
Intervention Type: Other
Study Phase: Phase 1
10-day Decitabine Versus Conventional Chemotherapy (3+7) Followed by Allografting in AML Patients ≥ 60 Years: a Randomized Phase III Study of the EORTC Leukemia Group, CELG, GIMEMA and German MDS Study Group
10-day Decitabine Versus Conventional Chemotherapy (3+7) Followed by Allografting in AML Patients ≥ 60 Years: a Randomized Phase III Study of the EORTC Leukemia Group, CELG, GIMEMA and German MDS Study Group
Enrollment Status: Unknown
Publish Date: February 15, 2023
Intervention Type: Drug
Study Drugs: Decitabine, Daunorubicin, Cytarabine, Idarubicin, Etoposide
Study Phase: Phase 3
Geriatric Assessment Adapted Therapy for Ph- ALL Elderly Patients. GIMEMA Protocol LAL1104. EudraCT Code 2005-002156-17
Geriatric Assessment Adapted Therapy for Ph- ALL Elderly Patients. GIMEMA Protocol LAL1104. EudraCT Code 2005-002156-17
Enrollment Status: Completed
Publish Date: October 12, 2022
Intervention Type: Procedure
Study Phase: Phase 2
Prospective Survey on Severe Infections During a Multicenter Study of Risk-adapted, MRD-directed Therapy for Young Adults With Newly Diagnosed Acute Myeloid Leukemia.
Prospective Survey on Severe Infections During a Multicenter Study of Risk-adapted, MRD-directed Therapy for Young Adults With Newly Diagnosed Acute Myeloid Leukemia.
Enrollment Status: Terminated
Publish Date: October 12, 2022
Intervention Type: Other
National Treatment Program of Philadelphia Chromosome-negative Adult Acute Lymphoblastic Leukemia With Pegylated Asparaginase Added to a Lineage-Targeted Risk- and Minimal Residual Disease-Oriented Strategy
National Treatment Program of Philadelphia Chromosome-negative Adult Acute Lymphoblastic Leukemia With Pegylated Asparaginase Added to a Lineage-Targeted Risk- and Minimal Residual Disease-Oriented Strategy
Enrollment Status: Completed
Publish Date: September 08, 2021
Intervention Type: Procedure, Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

157 Total Publications

Correction: Niscola et al. Acute Myeloid Leukemia in Older Patients: From New Biological Insights to Targeted Therapies. Curr. Oncol. 2024, 31, 6632-6658.
Correction: Niscola et al. Acute Myeloid Leukemia in Older Patients: From New Biological Insights to Targeted Therapies. Curr. Oncol. 2024, 31, 6632-6658.
Journal: Current oncology (Toronto, Ont.)
Published: May 27, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. De Fabritiis's expertise for a condition
ConditionClose
    View All 13 Advanced Conditions
    View All 20 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile